| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Sclareol targets multiple pathways involved in cancer cell proliferation, inflammation, and immune regulation. It inhibits DNA synthesis and induces cell cycle arrest at the G0/G1 phase, preventing cancer cell proliferation. Sclareol induces apoptosis independent of p53, making it effective against cancers with p53 mutations. The compound also exhibits anti-inflammatory activity by inhibiting the expression of MMPs, iNOS, and COX-2 at the mRNA and protein levels. Additionally, sclareol suppresses the over-production of nitric oxide (NO) and prostaglandin E2 (PGE2).
|
|---|---|
| ln Vitro |
Sclareol exhibited cytotoxicity against 13 out of 14 human leukemia cell lines examined, with IC50 values ranging from 6.0 to 24.2 μg/mL. However, in the same dose range, it did not exhibit cytotoxicity against peripheral blood mononuclear leukocytes [1].
In vitro, sclareol inhibits growth and is cytotoxic to many human cancer cell lines. It inhibits DNA synthesis, induces arrest at the G0/G1 phase of the cell cycle, and induces apoptosis independent of p53 in human breast cancer cell lines. Sclareol also inhibits the expression of MMPs, iNOS, and COX-2 at the mRNA and protein levels, while increasing TIMP-1 expression. The compound suppresses the over-production of NO and PGE2. These in vitro studies confirm the anticancer, anti-inflammatory, and immune-regulatory activities of sclareol. |
| ln Vivo |
In vivo, sclareol has been studied for its anti-cancer and anti-osteoarthritic activities. The compound's ability to inhibit tumor growth and reduce inflammation suggests potential therapeutic applications in cancer and osteoarthritis. However, specific in vivo experimental details are limited in the available literature. Further in vivo studies would be required to fully characterize its efficacy and safety. Sclareol is also used in the flavor and fragrance industry.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cellular) assays for sclareol are not extensively documented. However, the compound's ability to inhibit specific enzymes such as iNOS, COX-2, or MMPs can be assessed using cell-free enzymatic assays. The compound's ability to scavenge free radicals can be evaluated using standard antioxidant assays such as DPPH or ABTS. These assays would help to elucidate the molecular mechanisms underlying its biological activities.
|
| Cell Assay |
In vitro cellular assays for sclareol are performed using cancer cell lines, including human breast cancer cell lines. Cells are treated with varying concentrations of sclareol, and cell viability is measured using MTT assays. DNA synthesis is assessed by [3H]thymidine incorporation. Cell cycle distribution is analyzed by flow cytometry to assess G0/G1 phase arrest. Apoptosis is evaluated using annexin V staining or caspase activity assays. The expression of MMPs, iNOS, COX-2, and TIMP-1 is measured by quantitative PCR or Western blotting.
|
| Animal Protocol |
In vivo animal experiments for sclareol are not extensively documented in the available literature. However, the compound could be evaluated in xenograft mouse models of human cancers to assess its anti-tumor activity. Mice bearing human tumor xenografts would be treated with sclareol via oral or intraperitoneal administration, and tumor growth inhibition would be monitored. The compound's anti-osteoarthritic effects could be evaluated in animal models of osteoarthritis.
|
| ADME/Pharmacokinetics |
Sclareol has a molecular weight of 308.50 g/mol and a molecular formula of C20H36O2. Detailed pharmacokinetic properties such as bioavailability, half-life, and tissue distribution have not been extensively reported in the available literature. As a diterpene, sclareol may have limited oral bioavailability and may undergo extensive metabolism. Further pharmacokinetic studies would be necessary to support its development as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Sclareol has been evaluated in preclinical studies and has been reported to be well-tolerated at effective doses. No significant toxicity has been reported in the available literature. As a natural product derived from clary sage, sclareol is generally considered to have a favorable safety profile. However, comprehensive toxicology studies would be necessary to fully assess its safety for clinical development.
|
| References | |
| Additional Infomation |
Sagerol is a latanol diterpenoid compound with the structure latan-14-ene, substituted with hydroxyl groups at positions 8 and 13. It has been isolated from clary sage (Salvia sclarea). Sagerol possesses various functions, including antibacterial activity, apoptosis induction, use as a fragrance, antifungal agent, and plant metabolite. It has also been reported in Aster oharai, Ptychanthus striatus, and several other organisms with relevant data. See also: Clary Sage Oil (partial).
Sclareol is a labdane-type diterpene isolated from clary sage (*Salvia sclarea*). It exhibits anticancer, anti-inflammatory, and immune-regulatory activities. Sclareol inhibits DNA synthesis, induces G0/G1 cell cycle arrest, and induces apoptosis independent of p53 in cancer cells. It also inhibits the expression of MMPs, iNOS, and COX-2. Sclareol is a research compound with potential applications in cancer and inflammatory diseases. It is also used in the flavor and fragrance industry. |
| Molecular Formula |
C20H36O2
|
|---|---|
| Molecular Weight |
308.4986
|
| Exact Mass |
308.271
|
| CAS # |
515-03-7
|
| PubChem CID |
163263
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
398.3±15.0 °C at 760 mmHg
|
| Melting Point |
95-100 °C(lit.)
|
| Flash Point |
169.1±15.0 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.490
|
| LogP |
5.54
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
429
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[C@]12CCCC([C@@H]1CC[C@@]([C@@H]2CC[C@](C)(C=C)O)(C)O)(C)C
|
| InChi Key |
XVULBTBTFGYVRC-HHUCQEJWSA-N
|
| InChi Code |
InChI=1S/C20H36O2/c1-7-18(4,21)13-9-16-19(5)12-8-11-17(2,3)15(19)10-14-20(16,6)22/h7,15-16,21-22H,1,8-14H2,2-6H3/t15-,16+,18-,19-,20+/m0/s1
|
| Chemical Name |
(1R,2R,4aS,8aS)-1-[(3R)-3-hydroxy-3-methylpent-4-enyl]-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1H-naphthalen-2-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~162.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.10 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.10 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2415 mL | 16.2075 mL | 32.4149 mL | |
| 5 mM | 0.6483 mL | 3.2415 mL | 6.4830 mL | |
| 10 mM | 0.3241 mL | 1.6207 mL | 3.2415 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
